Skip to content
10-Q

Quarterly Report

Aligos Therapeutics, Inc. ALGS

0000950170-25-063983

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Short Term Investments Q1 2025 · Mar 31, 2025 $64.1M
Short Term Investments Q1 2025 · Dec 31, 2024 $19.94M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $73.76M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $37M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.95M
Current Liabilities Q1 2025 · Dec 31, 2024 $21.74M
Total Liabilities Q1 2025 · Mar 31, 2025 $34.25M
Total Liabilities Q1 2025 · Dec 31, 2024 $99.07M
Current Assets Q1 2025 · Mar 31, 2025 $143.21M
Current Assets Q1 2025 · Dec 31, 2024 $62.14M
Total Assets Q1 2025 · Mar 31, 2025 $150.7M
Total Assets Q1 2025 · Dec 31, 2024 $70.09M
Shares Diluted restated Q1 2025 · Mar 31, 2024 6.25M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$22.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 $59.8M
Stockholders Equity Q1 2025 · Dec 31, 2023 $92.08M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$5.58
Eps Basic restated Q1 2025 · Mar 31, 2024 −$5.58
Sga Expense Q1 2025 · Mar 31, 2024 $6.67M
Rd Expense Q1 2025 · Mar 31, 2024 $16.37M
Net Income Q1 2025 · Mar 31, 2024 −$34.86M
Operating Income Q1 2025 · Mar 31, 2024 −$22.05M
Revenue Q1 2025 · Mar 31, 2024 $694K